HIT Consultant January 14, 2025
Jasmine Pennic

What You Should Know:

Medtronic (NYSE:MDT), a global leader in healthcare technology, announced it has received CE Mark approval for its groundbreaking BrainSense™ Adaptive deep brain stimulation (aDBS) technology in the European Union and the United Kingdom.

– The CE approval marks a significant advancement in personalized Parkinson’s disease treatment, offering patients in Europe access to a more responsive and tailored therapy.

BrainSense™ aDBS: A New Era of Personalized Parkinson’s Treatment

For three decades, deep brain stimulation (DBS) has been a valuable tool for managing Parkinson’s disease symptoms. This technology involves implanting a device that sends electrical signals to specific brain regions to disrupt abnormal nerve signals that cause tremors and other movement difficulties.

BrainSense™ aDBS takes...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Medical Devices
Medical device cybersecurity could be challenged by HHS staffing cuts
Lantheus completes acquisition of radiopharma firm Evergreen Theragnostics for up to $1B
Why A Security-First Approach Is Essential For Advancing MedTech
Tech-enabled Eargo, hearX merge to form new hearing aid company
Five Data Management Questions for MedTech Leaders

Share This Article